Dose-Response Relation Between Sulfonylurea Drugs and Mortality in Type 2 Diabetes Mellitus: A Population-Based Cohort Study

Simpson, S. H.·2006·Canadian Medical Association Journal

DOI 10.1503/cmaj.050748

Cited by (235)

Items 101–200 of 235

Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events
C. Marijn Hazelbag, Olaf H. Klungel, Tjeerd Pieter van Staa, Anthonius de Boer, Rolf H. H. Groenwold · 2015 · Annals of Epidemiology
Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Sarawut Kumphune, Siriporn Chaisin Chattipakorn, Nipon Chattipakorn · 2013 · Current Pharmaceutical Design
Synthesized nano particles of glimepiride via spray freezing into cryogenic liquid: characterization, antidiabetic activity, and bioavailability
Dalia Ali Gaber, Abdulrahman Sulaiman AlHuwaymili, Hessah S. Alhawas, Alhnouf A. Almutiri, Amal M. Alsubaiyel, Siham Abdullah Abdoun, Reem A. Almutairi · 2022 · Drug Delivery
AHRQ’s Comparative Effectiveness Research on Oral Medications for Type 2 Diabetes: A Summary of the Key Findings
Wendy L. Bennett, Lisa M. Balfe, Joanne M. Faysal · 2012 · Journal of Managed Care Pharmacy
Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents
Matteo Anselmino · 2008 · Journal of Diabetes and its Complications
Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study
Yen‐Chieh Lee, Chia‐Hsuin Chang, Yaa‐Hui Dong, Jou‐Wei Lin, Li‐Chiu Wu, Jing‐Shiang Hwang, Lee‐Ming Chuang · 2016 · International Journal of Cardiology
Inhibition of potassium channels in critical illness
Matthias Lange, Andrea Morelli, Martin Westphal · 2008 · Current Opinion in Anaesthesiology
Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
Berthold Hocher, Karoline von Websky, Christoph Reichetzeder · 2013 · Vascular Health and Risk Management
Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Sanjay Kalra · 2011 · PubMed
Cardiovascular Prevention in Patients with Diabetes and Prediabetes
Matteo Anselmino, H. Gohlke, Linda Mellbin, Lars Rydén · 2008 · Herz
Perioperative administration of gabapentin for shoulder arthroscopy: a prospective, randomized, double-blind, placebo-controlled study.
Dennis Spence, Jason Goff, Erin Mohan, Kirsten Bowen, Lisa Osborne, John P. Maye · 2011 · PubMed
Improvement of hyperglycaemia and metabolic syndromes in type 2 diabetic KKAy mice by oral treatment with [meso-tetrakis(4-sulfonatophenyl) porphyrinato]oxovanadium(IV)(4-) complex
Tapan Saha, Yutaka Yoshikawa, Hiromu Sakurai · 2007 · Journal of Pharmacy and Pharmacology
More Reasons to Say Goodbye to Glyburide
Matthew C. Riddle · 2010 · The Journal of Clinical Endocrinology & Metabolism
Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan
Huang‐Tz Ou, Yen‐Ting Chen, Ya‐Ming Liu, Jin‐Shang Wu · 2016 · Diabetes Research and Clinical Practice
Caring for uninsured patients with diabetes: designing and evaluating a novel chronic care model for diabetes care
Mohammad A. Khan, Arthur T. Evans, S Shah · 2010 · Journal of Evaluation in Clinical Practice
Tight control of hyperglycemia in type 2 diabetes mellitus
Thomas W. Donner · 2006 · Insulin
Review of approved pioglitazone combinations for type 2 diabetes
Thomas M. Forst, Markolf Hanefeld E, Andreas Pfützner · 2011 · Expert Opinion on Pharmacotherapy
Vascular KATP channels mitigate severe muscle O2 delivery-utilization mismatch during contractions in chronic heart failure rats
Clark T. Holdsworth, Scott K. Ferguson, Trenton D. Colburn, Alexander J. Fees, Jesse C. Craig, Daniel M. Hirai, David C. Poole, Timothy I. Musch · 2017 · Respiratory Physiology & Neurobiology
Real-World Effectiveness of Sitagliptin as Add-On Therapy in Patients With Type 2 Diabetes Mellitus
Tse-Ying Chen, Ching‐Jung Hsieh · 2014 · Postgraduate Medicine
How Health Systems World-wide Fail Type 2 Diabetics
Abdo S. Yazbeck, Son Nam Nguyen, María-Luisa Escobar · 2025 · Health Systems & Reform
Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing’s syndrome, acromegaly and neuroendocrine tumours
Valentina Guarnotta, Fabrizio Emanuele, Riccardo Salzillo, Maria Bonsangue, Carlotta Amato, Mariagrazia Irene Mineo, Carla Santos de Souza Giordano · 2023 · Frontiers in Endocrinology
Mice expressing a human KATP channel mutation have altered channel ATP sensitivity but no cardiac abnormalities
Rebecca H. Clark, Roope Männikkö, D Stuckey, Michaela Iberl, Kieran J. Clarke, Frances Mary Ashcroft · 2012 · Diabetologia
Summarizing the FIELD study: lessons from a ‘negative' trial
Vasilis Tsimihodimos, Dimitri P. Mikhailidis, Moses Elisaf · 2013 · Expert Opinion on Pharmacotherapy
Changing Patterns of Glucose-Lowering Medication Use in VA Nursing Home Residents With Diabetes, 2005 to 2011
Sei J. Lee, Irena Stijacic‐Cenzer, Caroline E. Barnhart, Keelan M. McClymont, Michael Alan Steinman · 2015 · Journal of the American Medical Directors Association
The joint effects of different types of glucose-lowering treatment and duration of diabetes on total and cardiovascular mortality among subjects with type 2 diabetes
Mykola D. Khalangot, Mykola D. Tronko, Victor I Kravchenko, Jaroslava Kulchinska, Gang Hu · 2008 · Diabetes Research and Clinical Practice
Vascular ATP‐sensitive K + channels support maximal aerobic capacity and critical speed via convective and diffusive O 2 transport
Trenton D. Colburn, Ramona E. Weber, K. Sue Hageman, Jacob T. Caldwell, Kiana Marie Schulze, Carl J. Ade, Bradley Jon Behnke, David C. Poole, Timothy I. Musch · 2020 · The Journal of Physiology
Optimizing Antidiabetic Treatment Options for Patients with Type 2 Diabetes Mellitus and Cardiovascular Comorbidities
Mark A. Malesker · 2008 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
25 years of pharmacoepidemiologic innovation: the Saskatchewan health administrative databases.
Nigel S. B. Rawson, Winanne Downey, Colleen Jean Maxwell, Roy West · 2011 · PubMed
Influencing Factors, Kinetics, and Pathways of Pesticide Degradation by Chlorine Dioxide and Ozone: A Comparative Review
Zhaoguo Liu, Riya Jin, Yina Qiao, Jiaoqin Liu, Zengdi He, Mengye Jia, Yu Ying Jiang · 2025 · Applied Sciences
The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
Sooyoung Shin, Hyunah Kim · 2016 · Therapeutics and Clinical Risk Management
Diabetes therapy‐focus on Asia: second‐line therapy debate: insulin/secretagogues
Roy Eldor, Itamar Raz · 2012 · Diabetes/Metabolism Research and Reviews
Sulfonylurea Glimepiride: A Proven Cost Effective, Safe and Reliable War Horse in Combating Hyperglycemia in Type 2 Diabetes
Udaya M. Kabadi · 2015 · Journal of Diabetes Mellitus
Glibenclamide Prevents Hypoglycemia-Induced Fatal Cardiac Arrhythmias in Rats
Candace M. Reno, Justin Bayles, Allie Skinner, Simon J. Fisher · 2018 · Endocrinology
Understanding the cardiovascular risk with non-insulin antidiabetic drugs
Vasilios Gabriel Athyros, Konstantinos P. Imprialos, Konstantinos Stavropoulos, Alexandros Sahinidis, Michael N. Doumas · 2019 · Expert Opinion on Drug Safety
Comment on: Evans JM, Ogston SA, Emslie-Smith A, Morris A (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936
Jeffrey A. Johnson, Scot H. Simpson, Dean T. Eurich, Sumit R. Majumdar · 2006 · Diabetologia
Cardiovascular Effects of Noninsulin, Glucose-Lowering Agents: Need for More Outcomes Data
Parag H. Joshi, Rita Rastogi Kalyani, Roger Scott Blumenthal, Thomas W. Donner · 2012 · The American Journal of Cardiology
Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes
Sang Ouk Chin, In Gyoon Ha, Sang Youl Rhee, Su Jin Jeong, Suk Chon, Sung Hoon Kim, Kyu Jeung Ahn, Sei Hyun Baik, Yongsoo Park, Moon Suk Nam et al. · 2020 · International Journal of Endocrinology
Pharmacosurveillance without borders: electronic health records in different countries can be used to address important methodological issues in estimating the risk of adverse events
Robyn M Tamblyn, Nadyne Girard, William Gregory Dixon, Jennifer S. Haas, David Westfall Bates, Thérèse Sheppard, Tewodros Eguale, David Llewellyn Buckeridge, Michał Abrahamowicz, Alan John Forster · 2016 · Journal of Clinical Epidemiology
Review: Sulphonylureas and cardiovascular risk: facts and controversies
Paul Elie Valensi, Gérard Slama · 2006 · The British Journal of Diabetes
Commentary on “Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus: International Task Force”
SK Singh · 2018 · Indian Journal of Endocrinology and Metabolism
Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
Stanley S. Schwartz · 2014 · Postgraduate Medicine
Retracted: Conventional steroids vs. dual-release hydrocortisone on metabolic, cardiovascular, and bone outcomes in adrenal insufficiency: a 10-year study
Valentina Guarnotta, Claudia Di Stefano, Laura Tomasello, Laura Maniscalco, Giuseppe Pizzolanti, Giorgio Arnaldi, Carla Santos de Souza Giordano · 2024 · European Journal of Endocrinology · Retracted
Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective
Pendar Farahani · 2018 · International Journal of Endocrinology
Strategies to enhance cardiovascular disease prevention in patients with diabetes
Matteo Anselmino, Lars Rydén · 2009 · Current Opinion in Cardiology
Manejo práctico de antidiabéticos orales en pacientes con enfermedad renal
Nicolás Roberto Robles Pérez-Monteoliva, Roberto Alcázar Arroyo · 2006 · Nefrología
A drug mix and dose decision algorithm for individualized type 2 diabetes management
Mila Nambiar, Yong Mong Bee, Yu En Chan, Ivan Ho Mien, Feri Guretno, David Carmody, Phong Ching Lee, Sing Yi Chia, Nur Nasyitah Mohamed Salim, Pavitra Krishnaswamy · 2024 · npj Digital Medicine
Frequency and Severity of Hypoglycemia in Type 2 Diabetes Mellitus Patients Treated with a Sulfonylurea-Based Regimen at University-Affiliated Hospitals in Korea: The Naturalistic Evaluation of Hypoglycemic Events in Diabetic Subjects Study
Yon Su Kim, Belong Cho, Woo Sik Kim, Sang‐Hyun Kim, In Hyeon Jung, Won-Yong Sin, Donghoon Choi, Sang Jae Lee, Chun Soo Lim, Kyung Pyo Kang et al. · 2019 · Korean Journal of Family Medicine
Optimizing clinical outcomes resulting from glucose‐lowering therapies in type 2 diabetes: increased confidence about the DPP ‐4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin
Craig J. Currie, Sarah E. Holden · 2014 · Diabetes Obesity and Metabolism
Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes
Kathryn M. Hurren, Emily P. Bartley, Jessica L. O’Neill, David L. Ronis · 2010 · Acta Diabetologica
Exploring the Distribution of Prescription for Sulfonylureas in Patients with Type 2 Diabetes According to Cardiovascular Risk Factors Within a Canadian Primary Care Setting.
Pendar Farahani, Shahriar Khan, Mark A. Oatway, Alison Dziarmaga · 2015 · PubMed
METFORMIN AND LACTIC ACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES – FROM PRIDE AND PREJUDICE TO SENSE AND SENSIBILITY
Νικόλαος Παπάνας, Christodoulos Monastiriotis, Dimitrios Christakidis, Efstratios S. Maltezos · 2009 · Acta Clinica Belgica
Sulfonylurea therapy is associated with increased NT-proBNP levels in the treatment of type 2 diabetes
Hugh D. Tildesley, Cristina M. Aydin, Andrew P. Ignaszewski, Jason Strelzow, Eugenia Yu, Greg Bondy · 2006 · International Journal of Cardiology
Influence of Glycemic Control on the Development of Diabetic Cardiovascular and Kidney Disease
Sandeep Ajoy Saha, Katherine R. Tuttle · 2010 · Cardiology Clinics
Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936
D. Raccah · 2007 · Diabetologia
Adverse Events Due to Oral Hypoglycemic Drugs
Arun Nanditha, Rebeccaa Eapen Vettath · 2024 · Springer eBooks
Optimal Glycemic Control in the Elderly: Where is the Evidence and Who Should Be Targeted?
Daniel Tessier · 2011 · Aging Health
Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
Andreas Pfützner, Alexander Weise, E Pfützner, Georg Lübben, Michael Morcos, Efstrathios Karagiannis, Matthias M. Weber, Thomas M. Forst · 2011 · PPAR Research
Lipid Effects and Cardiovascular Disease Risk Associated with Glucose-Lowering Medications
Barbara Elisabeth Stähli, Cathérine Gebhard, Jean‐Claude Tardif · 2015 · Current Cardiology Reports
Effect of Aloe vera on glycemic outcomes in patients with diabetes mellitus: a systematic review protocol
Narabjit Kaur, Ritin Santiago Fernandez, Jenny Sim · 2017 · The JBI Database of Systematic Reviews and Implementation Reports
Insulin as a First-Line Therapy in Type 2 Diabetes
Eberhard Standl, Oliver Schnell · 2008 · Diabetes Care
Prevention of Cardiovascular Complications of the Metabolic Syndrome: Focus on Pharmacotherapy
Andrew J. Krentz · 2006 · Metabolic Syndrome and Related Disorders
Two Commonly Used Methods for Exposure—Adverse Events Analysis: Comparisons and Evaluations
John Z. Duan · 2009 · The Journal of Clinical Pharmacology
Patient characteristics not described
S. Lofsky · 2006 · Canadian Medical Association Journal
Views of medicine as a profession
Wilhelm Kreyes · 2006 · Canadian Medical Association Journal
Views of medicine as a profession
Herbert H Nehrlich · 2006 · Canadian Medical Association Journal
Sulfonylureas and meglitinides: insights into physiology and translational clinical utility
Harold E. Lebovitz, Arne Melander · 2015 · Wiley eBooks
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Hiroaki Yagyu, Hitoshi Shimano · 2022 · Journal of Diabetes Investigation
Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes
Caroline Sirois, Jocelyne Moisan, Paul Poirier, Jean‐Pierre Grégoire · 2014 · Annals of Medicine
Translational Endocrinology & Metabolism: Metabolic Surgery Update
DEL PRATO, STEFANO, Lebovitz HE · 2012 · Translational endocrinology & metabolism
Gliclazide MR in the structure of antihyperglycemic therapy according to the data of Moscow region diabetes register
И. В. Мисникова, Yu. A. Kovaleva, Губкина Валерия Алексеевна, Alexander Vasil'evich Dreval' · 2022 · Diabetes Mellitus
[Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].
Franco Cosmi, Deborah Cosmi · 2010 · PubMed
Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88].
Vasco P Miranda, Mariana Rodrigues, Francisco Rocha‐Gonçalves, José Pedro L. Nunes · 2009 · PubMed
Efficacy and safety of Vildagliptin in the management of type 2 Diabetes Mellitus
H Iftekar, Kalaiselvan, N S Gyanendra · 2012 · Indian Journal of Pharmacy Practice
Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study
Thomas Wilke, S. Mueller, Antje Groth, Bjoern Berg, Niklas Hammar, Katherine Tsai, Andreas Fuchs, Stephanie Stephens, Ulf Maywald · 2015 · Journal of Diabetes & Metabolic Disorders
Impacts of early insulin treatment vs glimepiride in diabetic patients with background metformin therapy
Fu‐Shun Yen, Chih‐Cheng Hsu, Yuan‐Chih Su, James Cheng‐Chung Wei, Chii‐Min Hwu · 2021 · Medicine
A comment on ‘the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy’
Yoosoo Chang, Nam‐Kyong Choi, Seokyung Hahn, Byung‐Joo Park · 2007 · Pharmacoepidemiology and Drug Safety
Don't throw the baby out with the bath water: Mortality with combination metformin and sulfonylurea
John A. Tayek · 2007 · Diabetes/Metabolism Research and Reviews
Sulfonylureas Glimepiride and Gliclazide Prevent Pancreatic Cancer Progression by Modulating Capn2 and Strengthening Tumor Immunotherapy
Zilong Chen, Yuhuai Wang, Defu Zhao, Yunan Lin, Ling T. He · 2025 · Bratislavské lekárske listy/Bratislava medical journal
Use of electronic health records for the management of diabetes and its risk factors in the Principality of Asturias from 2014 to 2018
Miguel García‐Villarino, Carmen Lambert, Jesús M. de la Hera, Edelmiro Luis Menéndez Torre, José María Fernández Rodríguez-Lacín, Elías Delgado · 2024 · Endocrinología Diabetes y Nutrición
Diabetic Cardiomyopathy: Cardiac Changes, Pathophysiological Mechanisms, Biologic Markers, and the Available Therapeutic Armamentarium
Michael F. · 2012 · InTech eBooks
Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies
DAVID H. FITCHETT · 2015 · Canadian Journal of Diabetes
Treating Type 2 Diabetes Mellitus
Susan Herzlinger, Martin J. Abrahamson · 2009 · Springer eBooks
Clinical and Pharmacological Characterization of Sulfonylurea Preparations: Conclusions for Outpatient Practice
С. А. Голубев · 2024 · Рецепт
Combination therapy in type 2 diabetes mellitus
Muhammad A Abdul‐Ghani, Ralph Anthony DeFronzo, Roy Eldor · 2015 · Wiley eBooks
Cardiovascular safety of sulphonylurea: comment on the study by Monami et al.
Liang Du, Yihan Chen, Jiayu Shen, Yu Peng, Xin Sun · 2013 · Diabetes Obesity and Metabolism
Use of electronic health records for the management of diabetes and its risk factors in the Principality of Asturias from 2014 to 2018
Miguel García‐Villarino, Carmen Lambert, Jesús M. de la Hera, Edelmiro Luis Menéndez Torre, José María Fernández Rodríguez-Lacín, Elías Delgado · 2024 · Endocrinología Diabetes y Nutrición (English ed )
Personalized Diabetes Therapy Part 1—Functional Phenotyping as a Conceptual Basis for Individualized Treatment
Andreas Pfützner, Julia Jantz · 2026 · Journal of Personalized Medicine
Evaluación de un modelo de diabetestipo 2 para estudiar la actividad hipoglicemieante de la glibenclamida
Araceli Amaya Chávez, Emilia Dolores-Ledezma, Patricia Álvarez-Sánchez, Guillermo Ferreira-Rubio, Leobardo Manuel Gómez‐Oliván, Marcela Galar‐Martínez · 2007 · Americanae (AECID Library)
The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes
Erin D. Roe, NATALIE C. PON, Priscilla A. Hollander, Philip Raskin · 2013 · Diabetes Management
Kardiovaskuläre Effekte inkretinbasierter Therapien
Michael Lehrke, Nikolaus Marx · 2012 · Herz
Lower Cardiovascular Risk with Diabetic Drugs: A Paradigm Shift from Glucocentricity to Cardio Protectiveness
Bijaya Mohanty · 2017 · Diabetes Case Reports
Managing Chronic Coronary Artery Disease in Patients with Diabetes
Nikolaus Marx, Sebastian Reith · 2017 · Elsevier eBooks
Sexual dimorphism in vascular ATP‐sensitive K+ channel function supporting interstitial via convective and/or diffusive O2 transport
Trenton D. Colburn, Ramona E. Weber, Kiana Marie Schulze, K. Sue Hageman, Andrew G. Horn, Bradley Jon Behnke, David C. Poole, Timothy I. Musch · 2021 · The Journal of Physiology
A1c and mortality: An unexpected relationship in patients with advanced heart failure
John A. Tayek · 2006 · American Heart Journal
Ação do inibidor da enzima dipeptidil peptidase 4 sobre o pré-condicionamento isquêmico em pacientes portadores de diabetes mellitus tipo 2 e doença arterial coronariana estável
Rosa Maria Rahmi Garcia · 2012
EVALUATING THE ROLE OF HYPOGLYCEMIA & COMORBID ILLNESS ON DIABETES MANAGEMENT BEHAVIORS
Saumitra V. Rege · 2014
Diabetes mellitus in patients with coronary artery disease: cardiovascular risk assessment and impact of available treatments
Matteo Anselmino · 2008 · Figshare
Myocardial infarction and diabetes mellitus Studies on glucose lowering therapies and novel risk markers based on observations from the DIGAMI 2 trial
Linda Mellbin · 2010 · Figshare
CLINICAL ASPECTS ON GLUCOSE-LOWERING THERAPIES IN TYPE 2 DIABETES
Å. Nybäck‐Nakell · 2012 · Figshare
Glibenclamide: proven facts, perspectives, discussions
Наталья Ивановна Чепляева · 2013 · Problems of Endocrinology